| Field | Specification |
|---|---|
| Mfr No | |
| Cas No. | |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Product Overview
zamristobart (HV631046) is a research-grade recombinant antibody targeting CD85. Highlights- ●Research Grade — For PK/PD studies, assay development, and ADA research.
Specifications
| Host Species | Human |
|---|---|
| Species Reactivity | Human |
| Isotype | IgG4, kappa |
| Target | CD85j/LILRB1/ILT2 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| UniProt | Q8NHL6 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
Scientific Background
Leukocyte immunoglobulin-like receptor subfamily B member 1 is a ~70 kDa protein. Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis.
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Shiroishi, M. et al. (2006) The Journal of biological chemistry 281, 10439-47. PMID: 16455647
2. Dulberger, CL. et al. (2017) Immunity 46, 1018-1029.e7. PMID: 28636952
3. Bellon, T. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 3351-9. PMID: 11907092
4. Cosman, D. et al. (1997) Immunity 7, 273-82. PMID: 9285411
5. Fanger, NA. et al. (1998) European journal of immunology 28, 3423-34. PMID: 9842885
6. Li, C. et al. (2009) Proceedings of the National Academy of Sciences of the United States of America 106, 5767-72. PMID: 19304799
7. Fu, B. et al. (2017) Immunity 47, 1100-1113.e6. PMID: 29262349
8. Naji, A. et al. (2014) Journal of immunology (Baltimore, Md. : 1950) 192, 1536-46. PMID: 24453251
